Bioavailability of Empagliflozin and Pioglitazone Co-administration

Phase 1, randomised, open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve at steady state over a uniform dosing interval up to 10 days and Maximum measured concentration at steady state up to 10 days. Started Jun 2009; status: completed.